Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 17/20 | 0.58 |
| ▸ | ACACA | Q13085 | 9/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622428 | 0.90 | ACACB (0.48) | ACACBACACACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4519186 | 0.84 | NPC1 (0.52) | ACACBACACACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4514258 | 0.83 | SMN1; SMN2 (0.49) | ACACBACACACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4513929 | 0.83 | TDP1 (0.52) | ACACBCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL2622431 | 0.82 | L3MBTL1 (0.55) | ACACBCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL15252374 | 0.81 | SMN1; SMN2 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL4525186 | 0.81 | NPC1 (0.50) | ACACBACACACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18269847 | 0.80 | SMN1; SMN2 (0.48) | ACACBACACACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4512358 | 0.80 | SMN1; SMN2 (0.52) | ACACBCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL2622427 | 0.79 | TDP1 (0.46) | ACACBACACACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996567-B1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC (US) | 2013-09-18 | — | — | EP | claimed |
| US-8207350-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBOTT LABORATORIES (US) | 2012-06-26 | — | — | US | claimed |
| US-20090048298-A1 | Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome | ABBOTT LABORATORIES (US) | 2009-02-19 | — | — | US | claimed |
| US-20070219258-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES | 2007-09-20 | — | — | US | claimed |
| US-8207350-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBOTT LABORATORIES (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090048298-A1 | Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome | ABBOTT LABORATORIES (US) | 2009-02-19 | — | — | US | disclosed |
| US-20070219258-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219258-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885CYP1A2 706/4885 |
| US-20090048298-A1 | Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885CYP1A2 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.